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Abstract
Lineage survival oncogenes are activated by somatic DNA alterations in cancers arising from the 
cell lineages in which these genes play a role in normal development.1,2 Here we show that a peak 
of genomic amplification on chromosome 3q26.33, found in squamous cell carcinomas (SCCs) of 
the lung and esophagus, contains the transcription factor gene SOX2—which is mutated in 
hereditary human esophageal malformations3 and necessary for normal esophageal squamous 
development4, promotes differentiation and proliferation of basal tracheal cells5 and co-operates 
in induction of pluripotent stem cells.6,7,8 SOX2 expression is required for proliferation and 
anchorage-independent growth of lung and esophageal cell lines, as shown by RNA interference 
experiments. Furthermore, ectopic expression of SOX2 cooperated with FOXE1 or FGFR2 to 
transform immortalized tracheobronchial epithelial cells. SOX2-driven tumors show expression of 
markers of both squamous differentiation and pluripotency. These observations identify SOX2 as a 
novel lineage survival oncogene in lung and esophageal SCC.
To identify genomic aberrations in lung and esophageal SCCs, we determined copy number 
for 40 esophageal SCC DNA samples (29 primary tumors and 11 cell lines) and 47 primary 
lung SCC DNA samples using 250K Sty I Affymetrix single-nucleotide polymorphism 
(SNP) arrays. Data were analyzed using GISTIC (Genomic Identification of Significant 
Targets in Cancer)1,9, which scores the significance of recurrent gains or losses and 
identifies peak regions likely to contain the driver gene(s).
For lung SCC, the most significant amplification peak is located on chromosome segment 
3q26.33, with the next most significant peaks encompassing the tyrosine kinase genes EGFR 
on 7p11.2 and FGFR1 on 8p12 (Figure 1a; Table 1; Supplemental Table 1). In esophageal 
SCC, the most significant amplification peak spans the cyclin gene CCND1 on 11q13.2; 
additional amplifications are found at EGFR, FGFR1, chromosome segment 3q26.33 and on 
8q24.21 near MYC and POU5F1B (Figure 1b; Table 1; Supplemental Table 1). Significant 
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focal deletions including deletions of CDKN2A/B on 9p21.3 were also identified 
(Supplemental Table 1; Supplemental Figure 1a).
Chromosome segment 3q26.33 is amplified in 11 of the 47 (23%) lung and 6 of the 40 
(15%) esophageal SCCs analyzed, as defined by SNP array-derived copy number of 3.6 or 
greater, which is generally a significant underestimate due to high tumor ploidy, normal 
DNA admixture, or signal saturation at high copy number. As five of the six amplified 
esophageal SCCs cases were cell lines, we performed fluorescence in situ hybridization 
(FISH) on tissue microarrays (TMA) from 63 independent primary esophageal SCC samples 
and noted amplifications in 7 of 63 cases to confirm recurrent amplifications in primary 
tumors (data not shown).
The peaks on chromosome segment 3q26.33 occur within a previously defined focus of 
amplification within 3q26-3q28 in SCCs10,11 containing candidate oncogenes including 
TP63,12 PIK3CA13 and DCUN1D1.14 In our lung SCC analysis, the peak contains four 
genes (SOX2, ATP11B, DCUN1D1, and MCCC1) (Figure 1c; Table 1). In esophageal SCC, 
the 3q amplification peak includes only one annotated gene, SOX2 (Figure 1d; Table 1). 
Even for those samples with the highest copy number at PIK3CA and TP63, SOX2 is 
amplified to higher levels in the majority of these samples (Supplemental Figure 1b). While 
these results argue that SOX2 is a target of amplification, the absence of other genes from a 
GISTIC peak does not exclude an oncogenic role, nor does it exclude polygenic 
contributions. Indeed, one lung SCC sample did harbor higher amplification at DCUN1D1/
ATP11B than at SOX2 (Supplemental Figure 1b), and also one lung SCC sample showed 
amplification at 183.03–183.27 Mb on chromosome 3, syntenic to the region containing 
lincRNA-Sox2, a non-coding RNA identified as a target of Sox2 in mouse ES cells.15
To evaluate the impact of 3q26.33 amplification on SOX2 expression, we measured SOX2 
mRNA levels by quantitative RT-PCR in 27 lung SCCs for which matched SNP array data 
and RNA were available. Cases with SOX2 amplification had higher mRNA expression (p-
value= 0.001; Supplemental Figure 2a–b). We noted several cases without 3q26.33 
amplification with high SOX2 mRNA expression, suggesting that mechanisms other than 
amplification also can induce SOX2 overexpression. For esophageal SCC, we also 
documented the correlation of amplification and expression using immunohistochemistry 
and FISH on matched TMAs (Supplemental Figure 2c).
We next evaluated the essentiality of genes within and near the amplification peak at 
3q26.33 for SCC cell lines bearing the amplification. We performed an arrayed RNAi screen 
targeting SOX2, ten neighboring genes, two additional candidates (PIK3CA and TP63) and 
control short hairpin RNAs (shRNA) specific for GFP and LacZ (Supplemental Table 2). 
Three to ten independent shRNAs were tested and analyzed after introduction into four SCC 
cell lines (esophageal lines TE10 and TT and lung lines NCI-H520 and HCC95) that harbor 
3q26.33 amplification and two control lung adenocarcinoma cell lines that lack 3q26.33 
amplification, NCI-H1437 and NCI-H1355.
Each shRNA construct was evaluated for its differential impact on proliferation, comparing 
its effect on the four amplified SCC lines to the two control cell lines. Expression of several 
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independent shRNAs targeting SOX2 reduced proliferation of the SCC cell lines compared 
to their effects in controls (Figure 2a). Analysis with the RIGER16,17 algorithm shows that 
suppression of SOX2 has the largest differential anti-proliferative effects on the 3q26.33 
amplified SCC cell lines among all genes tested (Figure 2a). Since prior work had 
implicated DCUN1D1 as a potential transforming oncogene14 we further validated the 
results of shRNA constructs targeting this gene and noted consistently less effect for 
knockdown of this gene relative to SOX2 (Supplemental Note; Supplemental Figure 3a–b). 
These observations suggest that SOX2 is an essential gene in SCCs with 3q26.33 
amplifications.
To determine in more detail the requirement for amplified SOX2, we examined cell lines 
expressing SOX2-directed or control shRNAs (shSOX2a, shSOX2b and shGFP) (Figure 2b). 
Suppression of SOX2 with either of two shRNA constructs reduced proliferation in the four 
3q26.33-amplified lines but not in controls without appreciable Sox2 expression (Figure 2c). 
We next evaluated anchorage-independent growth. TE10, TT and NCI-H1355 were not 
tested as these cell lines fail to form colonies in soft agar. ShRNA targeting SOX2 decreases 
colony formation in SOX2-amplified HCC95 and NCI-H520 cells compared to NCI-H1437 
cells (Figure 2d). Further results suggest that the reduction in anchorage-independence upon 
SOX2 knockdown exceeds the reduction in proliferation and that SOX2 is essential for some 
tumor cells with lower-level copy-gain at 3q26.33 (Supplemental Note; Supplemental Figure 
3c–d).
To confirm that the effects of SOX2 shRNA are attributable to SOX2 suppression, we tested 
whether we could rescue the effects of suppression of SOX2 with ectopic wild-type SOX2 or 
SOX2 R74P, a loss-of-function DNA-binding domain mutant identified in a patient with 
congenital tracheoesophageal fistula3. We introduced wild-type and mutant SOX2 into 
HCC95 cells and subsequently introduced shSOX2b, which targets the SOX2 3′ UTR. 
Expression of wild-type SOX2 restored anchorage-independent growth, whereas SOX2 R74P 
or GFP control failed to do so (Figure 2e). These observations demonstrate a clear 
requirement for SOX2 and argue against the possibility that the effects of shSOX2b on 
HCC95 cells are due to off-target toxicity.
We next examined the ability of SOX2 to transform immortalized tracheobronchial epithelial 
(AALE) cells.18 As SOX2 alone was not transforming, we searched lung SCC expression 
data19 for genes whose expression correlates with SOX2 expression (Supplemental Table 3) 
as candidates for co-operative transformation. The most highly correlated gene is FOXE1, a 
forkhead transcription factor gene on chromosome 9q22.33, which is also the locus of the 
most significant germ-line risk allele for thyroid cancer (followed by the NKX2-1 locus).20 
FOXE1 is expressed in the epithelium of the developing esophagus,21 and congenital 
mutations cause cleft palate and hypothyroidism.22 Another highly correlated gene, the 
receptor tyrosine kinase gene FGFR2, was of particular interest given that activating 
mutations are observed in lung SCC.23
While neither SOX2 nor FOXE1 ectopic expression alone was transforming, their co-
expression induced anchorage-independent growth (Figure 3a). However, we were unable to 
demonstrate a stable physical interaction of Sox2 and FoxE1 with co-immunoprecipitation 
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(data not shown), the suppression of FOXE1 with RNAi failed to reduce proliferation of 
SCC cell lines, and FoxE1 protein was not appreciably expressed in all SOX2-dependent 
SCC lines (data not shown), suggesting that FOXE1 is not broadly required for SOX2 
function.
To investigate potential cooperation between SOX2 and FGFR2, we similarly generated 
stable AALE lines by ectopic expression of SOX2, wild-type FGFR2 in the IIIb or IIIc 
splice variants, or both genes. Neither SOX2 nor FGFR2 expression alone could transform 
AALE cells, but the combination of SOX2 with the FGFR2 IIIb isoform found in epithelial 
cancers promoted anchorage-independent growth (Figure 3b). In contrast, expression of the 
‘mesenchymal’ isoform IIIc failed to transform these cells with SOX2 (Figure 3b). These 
results demonstrate that SOX2 can be transforming with multiple cooperating genes. Further 
work will be required to elaborate the genes which can act with SOX2 in tumorigenesis and 
the subtypes of tumors in which these genes are active.
In prior reports, we and others have identified that the developmental transcription factor 
NKX2-1 (or TITF1) is an amplified lineage survival oncogene in lung adenocarcinoma.
1,24,25,26 Within the primitive foregut there is reciprocal expression of Nkx2.1 and Sox2 in 
compartments that form the trachea and esophagus, respectively.4 Experimentally, Nkx2.1−/
− mice form hypoplastic lungs that stem from an undivided foregut with Sox2+/p63+ 
squamous epithelium.4 By contrast, mice that express a hypomorphic Sox2 allele develop 
tracheoesophageal fistulae and form an esophagus with a ciliated Nkx2.1+/p63− mucosa.4 
Hypothesizing that SOX2 may similarly represent a lineage survival oncogene, we compared 
the expression and amplification patterns of these two genes between lung adenocarcinomas 
and SCCs. We found SOX2 amplifications to be enriched in the lung SCC tumor population, 
while NKX2-1 amplification was enriched in lung adenocarcinoma (Supplemental Figure 
4a–b), consistent with a previous study of NKX2-124 and with a report that the copy-number 
of lung adenocarcinoma and SCC are distinguished by SCC-specific amplification 
chromosome 3q at 180–200 Mb.27 SNP array analysis from multiple adenocarcinoma 
lineages including esophageal adenocarcinomas failed to identify significant SOX2 
amplification (Beroukhim et al; submitted). Furthermore, mRNA expression data19,28 show 
that SOX2 mRNA levels are significantly higher in the lung SCC population compared to 
adenocarcinomas while NKX2-1 expression is significantly higher in adenocarcinomas 
(Supplemental Figure 4c–d). The complementary roles of SOX2 and NKX2-1 in distinct 
cancer lineages thus parallel their actions in development.
In addition to its role in the development and maintenance of esophageal and tracheal 
tissues, SOX2 is also a key factor in pluripotency and one of the factors that allows 
reprogramming of mature cells to pluripotent stem cells.6,7,8 Although the lineage-
restricted nature of SOX2 amplifications in lung and esophageal SCC argues for a role as a 
lineage survival oncogene, we sought to determine how SOX2’s role as a pluripotency factor 
could contribute to its oncogenic activity. Expression analysis across other tumor lineages 
has identified signatures of embryonic stem cells (ES cells) in subsets of tumors; these 
tumors tend to be poorly differentiated and associated with decreased survival.29 Querying 
lung SCC expression data with these signatures, we noted ES-like signatures and expression 
of targets of the core ES transcription factors in tumors with higher SOX2 expression (Figure 
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4a). However, patients presenting with lung SCC tumors exhibiting the ES-signature had 
improved survival compared to those without the signature (p-value for Kaplan-Meier plot 
0.03; not shown), and we did not identify significant association of SOX2 amplification or 
expression with clinical grade.
In contrast, expression of SOX2 correlates with markers of squamous differentiation in lung 
SCCs. TP63 and KRT6A, which encode for the squamous markers p63 and cytokeratin 6A, 
respectively, were among the 50 transcripts most correlated with SOX2 expression in lung 
SCCs (Supplemental Table 3). When SOX2 was ectopically expressed in the lung 
adenocarcinoma line NCI-H2009, both TP63 and KRT6A were induced (Figure 4b), 
demonstrating actions of SOX2 that promote squamous identity rather than de-differentiation 
to a pluripotent state, thus consistent with a role as a lineage survival oncogene.
This is the first report to show that SOX2 is an amplified oncogene in lung or esophageal 
SCC. SOX2 has critical roles in foregut development where it regulates initial dorsal/ventral 
patterning4, shapes epithelial-mesenchymal interactions and is required for proper 
differentiation of both the squamous esophagus4 and of multiple respiratory cell types.5 
SOX2 retains essential functions in the adult foregut where it is expressed in the proliferative 
basal esophagus30 and in the putative tracheal and airway stem cells5,31 where SOX2 is 
necessary for proliferation and response to injury.5 SOX2-driven SCCs likely co-opt 
multiple functions regulated by SOX2 in the normal foregut and may activate additional 
pathways controlled by SOX2 in early pluripotent cells. Given the complexity of these 
functions and the involvement of interactions of multiple cell types, further study of the 
oncogenic function of SOX2 will require engineered animal and organotypic tissue culture 
models. The elucidation of SOX2-dependent pathways in these models may identify novel 
therapeutic vulnerabilities in SCC and may uncover additional common pathways between 
cancer, normal development and the maintenance of pluripotency.
METHODS
Tumor Samples
DNA was provided for 47 lung SCC tumors with 17 matched normal samples (M.S.T, 
L.R.C., M.S.B and K.K.W), 29 esophageal SCCs and 11 matched normal samples (H.N., 
D.B.S, I.C., U.R.Jr., S.K.M. and A.K.R), and 11 esophageal SCC cell lines (A.K.R). Clinical 
information is listed in Supplemental Table 1. Primary tumors were all fresh-frozen with 
efforts to use samples with tumor content >70%. Tissue microarrays (TMAs) of esophageal 
SCC were provided by H.N., D.B.S and A.K.R..
SNP Array Experiments and Analysis
DNA was genotyped using the Sty I chip of the 500K Human Mapping Arrays (Affymetrix 
Inc).1 Data were analyzed using GISTIC.1,9 Copy number estimates were obtained using a 
tangent normalization, in which tumor signal intensities are divided by signal intensities 
from the linear combination of normal samples that are most similar to the tumor 
(manuscript describing methodology in preparation). After data normalization and 
segmentation/smoothing, GISTIC scores each SNP locus (G-score) as the product of 
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frequency and mean amplitude of amplifications. Only amplifications exceeding log2 copy 
number ratio of 0.848 above diploid for amplifications or of 0.737 below diploid for 
deletions were included as has been standard in copy-number analyses with SNP arrays.1 
This copy-number threshold for amplifications is lower than what is conventionally used to 
score FISH as done below. SNP array copy-numbers are diminished due to admixture of 
DNA from normal tissue and from microarray probe saturation effects leading to attenuation 
of inferred copy-number. G-scores were compared against a null model to determine a false 
discovery rate (q-value). Peaks with q-values below 0.005 were considered. Genomic 
coordinates of peaks of amplification were identified after capping copy number estimates at 
a log2 value of 1.0 to minimize peak calling due to hyper-segmentation; peak-finding also 
employed a peel-off step to remove the peak borders defined by the single sample(s) 
responsible for the minimal common regions. Genomic positions are mapped the hg18 
genome build.
Two-Color Interphase FISH Assay
Probes for SOX2 (clone CTD-2348H10) and reference (clone RP11-286G5) were obtained 
from the BACPAC Resource Center (Oakland, CA) and also from Invitrogen (Carlsbad, 
CA). Tissue hybridization, washing, and color detection were performed as described 
previously.32 The samples were analyzed under a 60x oil immersion objective using an 
Olympus BX-51 fluorescence microscope, and the CytoVision FISH imaging and capturing 
software (Applied Imaging, San Jose, CA). Semi-quantitative evaluation of the assays was 
independently performed by three evaluators (S.P., C.J.L. and P.W.). Samples were called as 
high-level amplification if ten or more inferred copies of SOX2 were detected.
Cell Lines and Culture Conditions
AALE cells were generated as previously described.18 HCC95, NCI-H1355, NCI-H2009 
and NCI-H1437 were provided by J.D.M. NCI-H520 cells were purchased from ATCC. TT, 
TE10 and TE11 cell lines were provided by A.K.R.. Lung cancer cell lines were maintained 
in RPMI with 10% fetal bovine serum. Esophageal SCC lines were maintained in DMEM 
with 10% fetal bovine serum. AALE cells were grown in SAGM media (Lonza). NIH-3T3 
cells (ATCC) were grown in DMEM with 10% calf serum. All cells were grown in 1mM 
penicillin/streptomycin cells other than AALE’s also were grown with 2mM L-Glutamine.
RNAi Screen
Lentiviral vectors containing shRNA sequences were obtained from the RNAi Consortium 
(TRC) (http://www.broadinstitute.org/rnai/trc; Supplemental Table 2). For three genes, 
FXR1, MCCC1 and PIK3CA, the TRC had performed knockdown validation; for these 
genes the three top-scoring constructs were used. For the remaining 10 genes (SOX2, 
MCF2L2, DNAJC19, TTC14, KLHL6, DCUN1D1, B3GNT5, TP63, ATP11B, LAMP3), all 
shRNAs in the TRC collection (five to ten per gene) were used and analyzed including six 
shRNAs targeting SOX2. For the controls, two shRNAs against GFP and two against LacZ 
were included. Cells were plated in 384-well plates and on the following day infected with 
1–3 ul of lentivirus with 8 ug/ml polybrene. Screens were performed with two replicates 
with and two replicates without puromycin, added 24 hours post-infection. Six days post-
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infection, wells were assayed using Cell-Titre Glo (Promega). Raw luminescence scores 
against the replicate wells with puromycin for a given shRNA construct in each cell line 
were normalized against readings for shGFP and shLacZ in that line. Analysis was 
performed with RIGER (RNAi Gene Enrichment Ranking)16,17 to compare the effects of 
each construct on the four 3q26.33-amplified lines to the construct’s effects in control cell 
lines to determine an enrichment score for each construct. Lower enrichment scores signify 
a greater decrease in proliferation in the 3q26.33-amplified cell lines. The enrichment scores 
were normalized against an enrichment score that would be generated by random 
permutation of an shRNA set of the same size to generate a normalized enrichment score for 
each gene. Comparison of the actual data to this permutation allows calculation of nominal 
P values and false discovery rate (FDR).
RNAi
Vectors with shRNA targeting SOX2 and GFP (Supplemental Table 2) were produced using 
TRC protocols (http://www.broadinstitute.org/rnai/trc). Cells were plated the day prior to 
infection and subsequently incubated with diluted virus in 8ug/mL polybrene for six hours. 
Puromycin was added the following day. After selection, cells were plated for proliferation 
or soft-agar assays. Protein was prepared for immunoblotting with anti-Sox2 polyclonal 
antibody (Abcam), anti-DCUN1D1 monoclonal antibody (Abcam) and anti-vinculin 
monoclonal antibody (Sigma) using standard techniques.
Retroviral Introduction of Genes
SOX2, and GFP were cloned into the pWZL vector with blasticidin resistance or the pBABE 
vector with puromycin resistance. FOXE1 and FGFR2 were cloned into the pBABE puro 
vector. Infections were performed with standard methods. Protein expression was confirmed 
via immunoblotting with antibodies to Sox2 (Abcam), vinculin (Sigma), FGFR2 (Santa 
Cruz) or FoxE1 (antibody kindly provided by Robert Di Lauro).
Anchorage-Independent Growth Assays
Cells were plated in triplicate in a top layer of growth media with 0.33% Noble Agar and 
plated onto a bottom layer of media with 0.5% Agar in a 6-well plate. Soft-agar colonies 
were counted at two to five weeks based upon growth rate. Images were acquired using 
Magnifire software by inverted microscopy (Olympus SZX9). ImageJ software (http://
rsb.info.nih.gov/ij/) was used to quantify colony number.
Comparison of anchorage-independent growth vs. non-anchorage-independent growth was 
performed in NCI-H520 cells. Equal numbers of cells (in triplicate) were plated with either 
Noble Agar as above or regular growth media. Colony numbers in soft-agar were quantified 
as above. Foci formed in cells in regular media were identified with crystal violet staining 
using standard methods with foci quantified as for soft-agar.
Cell Proliferation Assays
Cells with stable expression of each shRNA construct were plated onto four replicate wells 
of a 96-well plate; and three identical plates were prepared. Cell proliferation was assayed at 
24, 72 and 96 hours after plating with Cell-Titre Glo (Promega) on a Spectra Max5 plate 
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reader. Cell numbers at 72 and 96 hours were corrected for the ratio of shSOX2 to shGFP 
cells from the 24-hour reading to correct for plating unevenness. A representative 
experiment is shown with viability +/− a standard deviation of the reading from the four 
wells shown.
Expression Analysis
From existing raw expression files expression data were generated using a gene-centric CDF 
file.33 We applied RMA and quantile normalization34 and the matchprobes package in the 
Bioconductor framework35 to create one single data set. Only patients with pathologic stage 
I/II disease and less than 80 years old at diagnosis had their tumor’s expression profile 
included in the analysis. To identify genes linked to SOX2, we identified the 10 lung SCCs 
with the highest and 10 lowest SOX2 expressions. To identify correlated genes, differential 
expression was calculated using the same package in Bioconductor.36 We used gene-set 
expression analysis37 to assess whether the signatures that define ES cell identity are active 
and related to SOX2 expression level in lung SCC tumors. SOX2 mRNA expression was 
characterized as high and low in cases with expression 0.5 standard deviations above or 
below the mean, respectively. The analysis utilized nine gene sets that were previously 
defined to be over-expressed in ES cells and performed as previously described.29
Real-Time PCR Assays
For expression analysis, RNA was extracted from cells using the Qiagen RNeasy kit and 
cDNA prepared with the Qiagen QuanTiTECT cDNA synthesis kit. All real-time PCRs 
were performed in triplicate with Power PCR SYBR Green Master Mix (Applied 
Biosystems) on a 7300 Real-Time PCR System (Applied Biosystems) with results 
normalized to GAPDH expression. Primers are listed in Supplemental Table 2.
Immunohistochemistry
TMAs were stained with a polyclonal Sox2 antibody (Chemicon) at 1:5000 dilution 
following Dako antigen retrieval38. After staining, we scanned the TMAs with the ZEISS 
MIRAX Scanner (Zeiss, Oberkochen, Germany) and then used the AxioVision Software to 
measure the grey scale value. Protein expression was quantified by the grey scale values of 
the epithelial cells and defined as a value from 0 (black) to 255 (white). For statistical 
analysis, values were inverted so that higher expression (black) corresponded to higher 
numerical values.
Statistical Analysis
For comparisons of all continuous variables between experimental groups, Student’s T-tests 
were used. Effects of SOX2 RNAi on cellular proliferation was modeled by fitting the 
growth curve of each cell line to an exponential growth model using GraphPad Prism 
software. Modeled growth curves for each shSOX2-expressing cell line were compared to 
that for the appropriate shGFP-expressing cell line curve; F-tests were used to determine p-
value. P-values < 0.05 were considered significant; Bonferroni correction was performed for 
all experimental results in cell lines.
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Figure 1. Recurrent genomic amplifications of 3q target SOX2 in lung and esophageal squamous 
cell carcinomas
A) Plots of recurrent high-level amplifications in 47 SCCs of the lung from GISTIC analysis 
of SNP array data. X-axis shows the G-score (top) and false discovery rate (q-value; bottom) 
for recurrent amplification across the genome with a green line demarcating an arbitrary 
FDR cut-off of 0.005. Labels on right denote the position of peaks of the most significantly 
altered regions. B) Depiction of GISTIC amplification peaks for 40 esophageal squamous 
cell carcinomas (29 primary tumors and 11 cell lines) C) Plot of copy-number data from 
chromosome 3q from lung SCC. Each sample is represented with a vertical line from 
centromere (top) to telomere (bottom). Areas of red indicate gain; blue indicates loss. The 
positions of SOX2 and TP63 are noted with horizontal lines. An inset box shows the 10-Mb 
region centered on SOX2 in greater detail in the 15 samples with highest SOX2 copy 
number. The grey lines depict the positions of the two nearest RefSeq genes to SOX2--
ATP11B and DNAJC19--as well as PIK3CA. D) Plot of copy-number on chromosome 3q in 
esophageal SCC as described for panel C.
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Figure 2. SOX2 knockdown via RNAi reduces anchorage-independent growth and proliferation 
of SOX2-overexpressing cell lines
A) RIGER analysis of shRNA against SOX2 and genes neighboring SOX2. Differential 
effects of each shRNA construct on proliferation of the four 3q26.33-amplified SCC cell 
lines was calculated by comparison of the effect of each shRNA construct in the SCC cell 
lines compared to the construct’s effect in two control lung adenocarcinoma cell lines. Blue 
lines represent differential proliferation scores for each shRNA construct. Negative 
enrichment scores represent reduced proliferation in the four SCC cell lines. Red lines 
represent the normalized enrichment score calculated for each gene based upon the 
proliferative effect of all shRNAs to that gene compared to effects of other shRNAs in this 
screen. False discovery rates (FDRs) for significant enrichment are listed below the graph; 
FDRs for SCC cell-specific reduced proliferation are shown in plain text and for control 
cell-specific reduced proliferation in italics. All results were normalized against the effects 
of control shRNAs (shGFP, shLacZ) in each cell line. B)Anti-Sox2 and control anti-vinculin 
immunoblots of lysates from established tumor cell lines stably expressing shRNA targeting 
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SOX2 (shSOX2a or shSOX2b) or shRNA specific for green fluorescent protein (shGFP). 
HCC95 and NCI-H520 are lung SCC lines; TT and TE10 are esophageal SCC cell lines; and 
NCI-H1437 and NCI-H1355 are lung adenocarcinoma cell lines used as controls. C)Effect 
of SOX2-specific shRNA on viable cell numbers over time. Cells were measured at 24, 72 
and 96 hours after plating and corrected to equalize 24-hr values. Mean cell viabilities (+/- 
standard deviations of cell plated in quadruplicate) are plotted as percentage of 24-hour 
measurement at 24, 72 and 96 hours after plating. (Note, due to low standard deviations of 
some measurements, error bars are not visible for all data points.) Significance levels are 
indicated with * marking p<0.05, ** for p<0.01 and *** for p<0.001. D)Soft agar colony 
formation for HCC95 and NCI-H520 and control NCI-H1437 cells expressing SOX2 shRNA 
is shown relative to shGFP (+/− standard deviation) with p-values marked as above. E) Soft 
agar colony formation for HCC95 cells engineered with ectopic expression of GFP, SOX2 
or SOX2 R74P followed by infection with shSOX2b or shGFP. Data are shown relative to 
shGFP in HCC95-GFP cells (+/− standard deviation) with p-values marked as above. 
Immunoblots for Sox2 and vinculin are shown.
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Figure 3. SOX2 can transform FOXE1- or FGFR2IIIb-expressing immortalized 
tracheobronchial epithelial cells
A) Soft agar colony formation for AALE tracheobronchial epithelial cells expressing either 
SOX2, FOXE1 or the combination of factors. Graph shows number of colonies (+/− standard 
deviation of experiment) with p-values labeled with asterisks as in Figure 2. Also pictured 
are representative soft-agar images and immunoblots showing expression of Sox2 and 
FoxE1. B) Soft agar colony formation data (+/− standard deviations), immunoblots and 
representative soft-agar images from co-transformation assays in AALE cells with SOX2 
and FGFR2 IIIb and FGFR2 IIIc ectopic expression.
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Figure 4. SOX2 induces expression of markers of both pluripotency and squamous 
differentiation
A) The percentages of lung SCC tumors showing over-expression of each of nine gene sets 
that are characteristically induced in ES cells are shown for samples with and without 
elevated SOX2 expression. Gene sets for which the FDR-corrected hypergeometric 
enrichment P-value for the differences in over-expression in cases with and without SOX2 
over-expression are marked as in Figure 2. B) Quantitative RT-PCR for mRNA expression 
of squamous markers TP63 and KRT6A in NCI-H2009 cells with ectopic SOX2 compared to 
ectopic GFP with asterisks indicating p-values.
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Table 1
High-level amplifications in lung and esophageal squamous cell carcinomas
Lung Squamous Cell Carcinoma Amplifications
Cytoband q value Peak Boundaries Genes in Peak Candidate Target(s)
3q26.33 4.8E-21 182.29–184.44 4 SOX2
8p12 1.5E-07 38.25–39.72 10 FGFR1, WHSC1L1
7p11.2 5.2E-06 54.31–55.74 7 EGFR
Esophageal Squamous Cell Carcinoma Amplifications
Cytoband q value Peak Boundaries Genes in Peak Candidate Target(s)
11q13.3 4.1E-41 68.81–69.94 10 CCND1
7p11.2 6.3E-06 54.60–55.36 2 EGFR
3q26.33 6.0E-06 182.71–183.93 1 SOX2
8q24.21 0.003 128.35–128.70 2 MYC, POU5F1B
8p12 0.003 38.23–38.76 6 FGFR1, WHSC1L1, PPADC1B
GISTIC-defined peaks of high-level (inferred copy-number >3.6) recurrent genomic amplification in lung squamous cell carcinoma and esophageal 
squamous cell carcinoma.
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